UMIN試験ID | UMIN000039255 |
---|---|
受付番号 | R000044767 |
科学的試験名 | 眼部帯状疱疹の眼合併症に対するハッチンソン徴候の予後的価値:系統的レビューとメタ分析 |
一般公開日(本登録希望日) | 2020/01/29 |
最終更新日 | 2020/07/25 12:30:27 |
日本語
眼部帯状疱疹の眼合併症に対するハッチンソン徴候の予後的価値:系統的レビューとメタ分析
英語
Prognostic value of Hutchinson's sign for ocular complications in herpes zoster ophthalmicus: a systematic review and meta-analysis
日本語
眼部帯状疱疹の眼合併症に対するハッチンソン徴候の予後的価値:系統的レビューとメタ分析
英語
Prognostic value of Hutchinson's sign for ocular complications in herpes zoster ophthalmicus: a systematic review and meta-analysis
日本語
眼部帯状疱疹の眼合併症に対するハッチンソン徴候の予後的価値:系統的レビューとメタ分析
英語
Prognostic value of Hutchinson's sign for ocular complications in herpes zoster ophthalmicus: a systematic review and meta-analysis
日本語
眼部帯状疱疹の眼合併症に対するハッチンソン徴候の予後的価値:系統的レビューとメタ分析
英語
Prognostic value of Hutchinson's sign for ocular complications in herpes zoster ophthalmicus: a systematic review and meta-analysis
日本/Japan |
日本語
眼部帯状疱疹
英語
herpes zoster ophthalmicus
内科学一般/Medicine in general | 眼科学/Ophthalmology |
皮膚科学/Dermatology | 成人/Adult |
悪性腫瘍以外/Others
いいえ/NO
日本語
眼部帯状疱疹患者の眼合併症に対するハッチンソン徴候の予後的価値を調べる。
英語
This systematic review and meta-analysis aimed to investigate the prognostic value of Hutchinson's sign for ocular complications of herpes zoster ophthalmicus.
その他/Others
日本語
該当しない
英語
N/A
日本語
Occurrence of ocular involvement, defined as a sign of ocular manifestation (e.g. conjunctivitis, superficial keratitis, episcleritis, stromal keratitis, dendritic ulcer, scleritis, uveitis, vasculitis, optic neuritis, chorioretinitis, acute retinal necrosis).
Time point for analysis will be defined as 4 weeks or the closest time point to 4 weeks in a time span of 2 weeks to 6 months if data are not available.
英語
Occurrence of ocular involvement, defined as a sign of ocular manifestation (e.g. conjunctivitis, superficial keratitis, episcleritis, stromal keratitis, dendritic ulcer, scleritis, uveitis, vasculitis, optic neuritis, chorioretinitis, acute retinal necrosis).
Time point for analysis will be defined as 4 weeks or the closest time point to 4 weeks in a time span of 2 weeks to 6 months if data are not available.
日本語
Occurrence of severe ocular involvement (intraocular involvement: e.g. scleritis, uveitis, vasculitis, optic neuritis, chorioretinitis, acute retinal necrosis)
Time point for analysis will be defined as 4 weeks or the closest time point to 4 weeks in a time span of 2 weeks to 6 months if data are not available.
英語
Occurrence of severe ocular involvement (intraocular involvement: e.g. scleritis, uveitis, vasculitis, optic neuritis, chorioretinitis, acute retinal necrosis)
Time point for analysis will be defined as 4 weeks or the closest time point to 4 weeks in a time span of 2 weeks to 6 months if data are not available.
その他・メタアナリシス等/Others,meta-analysis etc
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
18 | 歳/years-old | 以上/<= |
適用なし/Not applicable |
男女両方/Male and Female
日本語
Inclusion criteria were as follows: published and unpublished observational studies with a control, or controlled clinical studies, including only Abstracts or Letters; studies in any language, from any country, and including length of follow-up; and outpatients or inpatients suspected or diagnosed with acute herpes zoster ophthalmicus.
英語
Inclusion criteria were as follows: published and unpublished observational studies with a control, or controlled clinical studies, including only Abstracts or Letters; studies in any language, from any country, and including length of follow-up; and outpatients or inpatients suspected or diagnosed with acute herpes zoster ophthalmicus.
日本語
Exclusion criteria were as follows: case reports and case series; children and patients with existing uveitis, glaucoma, corneal, and retinal diseases.
英語
Exclusion criteria were as follows: case reports and case series; children and patients with existing uveitis, glaucoma, corneal, and retinal diseases.
0
日本語
名 | 貴大 |
ミドルネーム | |
姓 | 水田 |
英語
名 | Takahiro |
ミドルネーム | |
姓 | Mizuta |
日本語
東京都立多摩総合医療センター
英語
Tokyo Metropolitan Tama Medical Center
日本語
皮膚科
英語
Department of Dermatology
1838524
日本語
東京都府中市武蔵台2-8-29
英語
2-8-29 Musashidai, Fuchu-shi, Tokyo, Japan
+81423235111
t.miz.cof.lif2120@gmail.com
日本語
名 | 貴大 |
ミドルネーム | |
姓 | 水田 |
英語
名 | Takahiro |
ミドルネーム | |
姓 | Mizuta |
日本語
東京都立多摩総合医療センター
英語
Tokyo Metropolitan Tama Medical Center
日本語
皮膚科
英語
Department of Dermatology
1838524
日本語
東京都府中市武蔵台2-8-29
英語
2-8-29 Musashidai, Fuchu-shi, Tokyo, Japan
+81423235111
t.miz.cof.lif2120@gmail.com
日本語
その他
英語
SRWS-PSG
日本語
SRWS-PSG
日本語
日本語
英語
日本語
無し
英語
N/A
日本語
N/A
日本語
自己調達/Self funding
日本語
英語
日本語
英語
日本語
英語
日本語
N/A
英語
N/A
日本語
N/A
英語
N/A
N/A
N/A
いいえ/NO
日本語
英語
日本語
英語
2020 | 年 | 01 | 月 | 29 | 日 |
未公表/Unpublished
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
開始前/Preinitiation
2020 | 年 | 01 | 月 | 01 | 日 |
2020 | 年 | 02 | 月 | 01 | 日 |
2022 | 年 | 02 | 月 | 01 | 日 |
日本語
[Search method]
Electronic search
MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL)
Other resources
World Health Organization International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov
Guidelines
1. European consensus-based (S2k) guideline on the management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis.
2. International Association for the Study of Pain (IASP) recommendations on management of herpes zoster
We will search for references in identified articles, and relevant authors will be contacted, if information is insufficient in the reports.
[Data extraction / Risk of bias assessment]
Two authors will independently extract data and assess risk of bias using the QUIPS tool (Hayden 2013).
[Meta-analysis]
We will implement using STATA. We will use random effects model.
We will create a "Summary of findings" table and will use the grades of recommendation, assessment, development, and evaluation (GRADE) approach to grade the certainty of the evidence.
We will include the following outcomes in the "Summary of findings" table:
1. Occurrence of ocular involvement
2. Ocular involvement: uveitis
[Subgroup analysis]
Perform the following subgroup analyses:
1. Patients' immune competence (HIV infection absent or present)
2. Point of first contact (up to and including 72 h from the onset of rash or longer than 72 h from the onset of rash)
3. Point of starting initial systemic antiviral drugs (up to and including 72 h from the first patient contact or longer than 72 h from the first patient contact)
[Sensitivity analysis]
Perform the following sensitivity analyses for the primary outcome:
1. Exclusion of unpublished studies (full reports versus Abstracts or unpublished articles)
2. Exclusion of studies defining Hutchinson's sign as the presence of rash only on the tip of the nose
英語
[Search method]
Electronic search
MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL)
Other resources
World Health Organization International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov
Guidelines
1. European consensus-based (S2k) guideline on the management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis.
2. International Association for the Study of Pain (IASP) recommendations on management of herpes zoster
We will search for references in identified articles, and relevant authors will be contacted, if information is insufficient in the reports.
[Data extraction / Risk of bias assessment]
Two authors will independently extract data and assess risk of bias using the QUIPS tool (Hayden 2013).
[Meta-analysis]
We will implement using STATA. We will use random effects model.
We will create a "Summary of findings" table and will use the grades of recommendation, assessment, development, and evaluation (GRADE) approach to grade the certainty of the evidence.
We will include the following outcomes in the "Summary of findings" table:
1. Occurrence of ocular involvement
2. Ocular involvement: uveitis
[Subgroup analysis]
Perform the following subgroup analyses:
1. Patients' immune competence (HIV infection absent or present)
2. Point of first contact (up to and including 72 h from the onset of rash or longer than 72 h from the onset of rash)
3. Point of starting initial systemic antiviral drugs (up to and including 72 h from the first patient contact or longer than 72 h from the first patient contact)
[Sensitivity analysis]
Perform the following sensitivity analyses for the primary outcome:
1. Exclusion of unpublished studies (full reports versus Abstracts or unpublished articles)
2. Exclusion of studies defining Hutchinson's sign as the presence of rash only on the tip of the nose
2020 | 年 | 01 | 月 | 25 | 日 |
2020 | 年 | 07 | 月 | 25 | 日 |
日本語
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000044767
英語
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044767
研究計画書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ仕様書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ | |
---|---|
登録日時 | ファイル名 |